Abstract 351P
Background
Waldenstrom macroglobulinemia (WM) is a very rare disease. It also known as lymphoplasmacytic lymphoma, a low grade-B cell lymphoproliferative neoplasm characterized by monoclonal IgM gammopathy. The diagnosis of WM is challenging and data regarding clinical features and treatment outcomes in Indonesia is limited. The aim of this study is to investigate clinical features, treatments and outcomes of WM patients in the tertiary referral cancer center in Jakarta, Indonesia.
Methods
This was a retrospective cohort study conducted in outpatient oncology clinic in a tertiary referral cancer center in Jakarta, Indonesia from 2022 until 2023. It included all patients with working diagnosis WM based on Waldenstrom Macroglobulinemia International Workshop Criteria. Demographic data, clinical features, treatments, and outcomes were collected.
Results
We evaluated a total of 8 patients. Most of the patients (62.5%) were male, with mean age 61.1 + 8.6 years old. All patients had symptoms of anemia such weakness, light-headedness, and shortness of breath. Median hemoglobin was 8.46 (6.0 – 13.1) g/dL. Mean immunoglobulin (Ig)M was 3832. Three (37.5%) patients had autoimmune hemolytic anemia (AIHA), and 3 (37.5%) patients had organomegaly. Seventy percent patients received systemic therapy, mostly (66.7%) with Cyclophosphamide Vincristine Prednisone (CVP) regiment. Among those who had systemic therapy, two (33.3%) patients died, and 1 (16.6%) patient transformed into acute myeloid leukemia (AML).
Conclusions
The clinical features of WM were male sex, elderly, anemia, had AIHA, high IgM and organomegaly. Most patients underwent systemic therapy but had unfavorable responses. Further studies should focus on predictors of survival on WM patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract